This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ChemoCentryx Bilan de santé
Santé financière contrôle des critères 4/6
Informations clés
10.5%
Ratio d'endettement
US$24.92m
Dette
| Ratio de couverture des intérêts | n/a |
| Argent liquide | US$328.62m |
| Fonds propres | US$236.53m |
| Total du passif | US$182.86m |
| Total des actifs | US$419.39m |
Mises à jour récentes de la santé financière
ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06
ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04
Recent updates
ChemoCentryx shareholders approve $4.7B merger with Amgen
Oct 18ChemoCentryx GAAP EPS of -$0.44 misses by $0.03, revenue of $11.76M misses by $9.89M
Aug 09ChemoCentryx: Revisiting The Investment Case
Jun 21ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Jun 06ChemoCentryx: Good Post-Approval Performance, But Needs More Time
Mar 03ChemoCentryx (NASDAQ:CCXI) Has Debt But No Earnings; Should You Worry?
Feb 11Analysts Are Betting On ChemoCentryx, Inc. (NASDAQ:CCXI) With A Big Upgrade This Week
Jan 21Checking In On ChemoCentryx
Dec 15Is ChemoCentryx (NASDAQ:CCXI) Using Debt In A Risky Way?
Oct 09ChemoCentryx: Make Or Break PDUFA Date For Avacopan May Not Go The Company's Way
Sep 29ChemoCentryx And Avacopan In ANCA-Associated Vasculitis: Making Amends
Aug 24Time To Worry? Analysts Just Downgraded Their ChemoCentryx, Inc. (NASDAQ:CCXI) Outlook
Aug 11ChemoCentryx: CRL Less Likely
Jul 25ChemoCentryx, Inc.'s (NASDAQ:CCXI) Intrinsic Value Is Potentially 34% Above Its Share Price
Jul 11ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jun 15ChemoCentryx reports avacopan in ANCA vasculitis at ERA-EDTA congress
Jun 08ChemoCentryx: CRL Likely
May 09ChemoCentryx downgraded on narrow Adcom backing, Tilray jumps on double upgrade; in today’s analyst action
May 07Chemocentryx shares plunge 47% as FDA report identifies concerns with vasculitis candidate
May 04When Will ChemoCentryx, Inc. (NASDAQ:CCXI) Become Profitable?
Mar 03ChemoCentryx (NASDAQ:CCXI) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Feb 04ChemoCentryx: Great Drug, Good Prospects, Uncomfortable Stock Price
Jan 14Have ChemoCentryx, Inc. (NASDAQ:CCXI) Insiders Been Selling Their Stock?
Dec 31Analyst Forecasts Just Became More Bearish On ChemoCentryx, Inc. (NASDAQ:CCXI)
Dec 23ChemoCentryx's avacopan flunks mid-stage study in rare kidney disease study
Dec 21Did The Underlying Business Drive ChemoCentryx's (NASDAQ:CCXI) Lovely 934% Share Price Gain?
Dec 13Are Investors Undervaluing ChemoCentryx, Inc. (NASDAQ:CCXI) By 25%?
Nov 22ChemoCentryx, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 10Analyse de la situation financière
Passif à court terme: CCXI's short term assets ($345.2M) exceed its short term liabilities ($76.1M).
Passif à long terme: CCXI's short term assets ($345.2M) exceed its long term liabilities ($106.8M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: CCXI has more cash than its total debt.
Réduire la dette: Insufficient data to determine if CCXI's debt to equity ratio has reduced over the past 5 years.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: CCXI has sufficient cash runway for more than 3 years based on its current free cash flow.
Prévisions de trésorerie: Insufficient data to determine if CCXI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.